2Shah PL, HanseU D, Lawson PR, et al. Pulmonary alveolar proteinosis: clinical aspects and current concepts on pathogenesis[J]. Thorax, 2000, SS(1): 67-77.
3Byun MK, Kim DS, Kim YW, et al. Clinical features and outcomes of idiopathic pulmonary alveolar proteinosis in Korean population[J]. J Korean Med Sci, 2010, 25(3): 393-398.
4Trapnell BC, Whitsett JA, Nakata K. Pulmonary alveolar proteinosis[J]. N EnglJ Med, 2003, 349(26): 2527-2539.
5Inoue Y, Trapnell BC, Tazawa R, et al. Characteristics of a large cohort of patients with autoimmune pulmonary alveolar proteinosis in Japan[J]. AmJ Respir Crit Care Med, 2008, 177(7): 7.52-762.
6Huizar I, Kavuru MS. Alveolar proteinosis syndrome: pathogenesis, diagnosis, and management[J]. Curr Opin Pulm Med, 2009, 15(5): 491-498.
7Beccaria M, Luisetti M, Rodi G, et al. Long-term durable benefit after whole lung lavage in pulmonary alveolar proteinosis [J]. Eur Respir J, 2004, 23(4): 526-531.
8Dranoff G, Mulligan RC. Activities of granulocyte-macrophage colony-stimulating factor revealed by gene transfer and gene knockout studies[J]. Stem Cells, 1994, 12(1): 173-182.
9Shibata Y, Berclaz PY, Chroneos ZC, et al. GM-CSF regulates alveolar macrophage differentiation and innate immunity in the lung through PU.1 [J]. Immunity, 2001, 15(4): 557-567.
10Sergeeva A, Ono Y, RJos R, et al. High titer autoantibodies to GM- CSF in patients with AML, CML and MDS are associated with active disease [J]. Leukemia, 2008, 22(4): 783-790.
